4-bromotetramisole has been researched along with Hepatoblastoma in 1 studies
4-bromotetramisole: available in levo & dextro form; L-form potent inhibitor of non specific alkaline phosphatase; RN given refers to cpd without isomeric designation
Hepatoblastoma: A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JA | 1 |
| Kang, YS | 1 |
| Lee, SH | 1 |
| Lee, EH | 1 |
| Yoo, BH | 1 |
| Lee, YS | 1 |
1 other study available for 4-bromotetramisole and Hepatoblastoma
| Article | Year |
|---|---|
Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channels and intracellular Ca(2+) release in HepG2 human hepatoblastoma cells.
Topics: Apoptosis; Caco-2 Cells; Calcium; Chlorides; Cystic Fibrosis Transmembrane Conductance Regulator; Da | 1999 |